Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

June 5, 2018

Primary Completion Date

June 30, 2023

Study Completion Date

November 18, 2025

Conditions
Advanced MelanomaRecurrent MelanomaStage III Cutaneous Melanoma AJCC v7Stage IIIA Cutaneous Melanoma AJCC v7Stage IIIB Cutaneous Melanoma AJCC v7Stage IIIC Cutaneous Melanoma AJCC v7Stage IV Cutaneous Melanoma AJCC v6 and v7Unresectable Melanoma
Interventions
BIOLOGICAL

Pembrolizumab

Given IV

BIOLOGICAL

Talimogene Laherparepvec

Given IL

Trial Locations (20)

36688

University of South Alabama Mitchell Cancer Institute, Mobile

37232

Vanderbilt University/Ingram Cancer Center, Nashville

43210

Ohio State University Comprehensive Cancer Center, Columbus

45069

University of Cincinnati Cancer Center-West Chester, West Chester

45219

University of Cincinnati Cancer Center-UC Medical Center, Cincinnati

46202

Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis

48038

Henry Ford Macomb Hospital-Clinton Township, Clinton Township

48183

Henry Ford Cancer Institute-Downriver, Brownstown

48202

Henry Ford Hospital, Detroit

48322

Henry Ford West Bloomfield Hospital, West Bloomfield

49201

Allegiance Health, Jackson

60153

Loyola University Medical Center, Maywood

64128

Kansas City Veterans Affairs Medical Center, Kansas City

66205

University of Kansas Hospital-Westwood Cancer Center, Westwood

84112

Huntsman Cancer Institute/University of Utah, Salt Lake City

85338

CTCA at Western Regional Medical Center, Goodyear

90033

Los Angeles General Medical Center, Los Angeles

USC / Norris Comprehensive Cancer Center, Los Angeles

90095

UCLA / Jonsson Comprehensive Cancer Center, Los Angeles

91105

Keck Medical Center of USC Pasadena, Pasadena

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT02965716 - Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma | Biotech Hunter | Biotech Hunter